# data[].attributes.body
A New York technology consultant who has worked with biotechnology and information technology firms spamming California, Florida, and Boston, Massachusetts, Richard DiVenuto has a strong interest in cell therapy to address complex diseases. A current area of focus for Richard DiVenuto centers on understanding COVID-19, which has impacted Americans across the country.

# data[].attributes.attachment_link.readable_text
A New York technology consultant who has worked with biotechnology and information technology firms spamming California, Florida, and Boston, Massachusetts, Richard DiVenuto has a strong interest in cell therapy to address complex diseases. A current area of focus for Richard DiVenuto centers on understanding COVID-19, which has impacted Americans across the country.

Novel coronavirus begins with symptoms such as fever, sore throat, body aches, and loss of taste or smell. In cases where the immune system does not successfully fight off SARS-CoV-2, the virus can progress down the windpipe and enter the lungs, where it can become deadly.

The threat centers on alveoli, which are air sacs at the end of distant, thin branches of the respiratory tree. Each alveolus has a single layer lining of ACE2-receptor rich cells. When functioning normally, oxygen can cross from the alveoli to the tiny capillaries that bring oxygen to the rest of the body. However, this is disrupted by the COVID-19 triggered response that the frontline white blood cells unleash, as part of the immune system response.

The inflammatory chemokine molecules released by white blood cells bring more immune cells into the battle and eliminate virus-infected cells. What is left behind is pus, a mixture of dead cells and fluid, which provides the underlying pathology of pneumonia.

While some patients recover from this stage, others may enter into a state of (ARDS) acute respiratory distress syndrome, in which blood oxygen levels decrease rapidly, and breathing becomes a struggle. Even being placed on a ventilator at this point may not be enough to prevent a fatality.

# data[].attributes.attachment_link.description
A New York technology consultant who has worked with biotechnology and information technology firms spamming California, Florida, and Boston, Massachusetts, Richard DiVenuto has a strong interest in cell therapy to address complex diseases. A current area of focus for Richard DiVenuto centers on understanding COVID-19, which has impacted Americans across the country.

# data[].attributes.body
An accomplished entrepreneur-advisor and innovative tactician who has worked extensively in Florida, New York, California, and Boston in Massachusetts, Richard DiVenuto serves as an advisor to two Biotechnology companies. In this role, Richard DiVenuto implements and monitors corporate stock options for the board of directors and employees. His current area of focus also includes stem cell therapies for cancers and autoimmune disorders.

# data[].attributes.attachment_link.readable_text
An accomplished entrepreneur-advisor and innovative tactician who has worked extensively in Florida, New York, California, and Boston in Massachusetts, Richard DiVenuto serves as an advisor to two Biotechnology companies. In this role, Richard DiVenuto implements and monitors corporate stock options for the board of directors and employees. His current area of focus also includes stem cell therapies for cancers and autoimmune disorders.

Chimeric antigen receptor T cells, also known as CAR T cells, are enhanced versions of T Cells with extreme capabilities to fight cancers. After the development of the first generation of these cells, additional modifications to enhance features and also mediate properly targeted response has led to the development of the second and third-generation CAR T cells. These cells have demonstrated sufficient capabilities when it comes to treating hematological malignancies that were previously thought to be incurable, which places CAR T cells in a position of significant advancement in the area of cancer immunotherapy.

Although autologous (patient's derived) T cells were the source at the initial phase of the study, this approach is costly since a special manufacturing process is often required for each patient and also significant time (weeks) is required before engineered versions of autologous T cells are ready for treatment purpose, the later which may be a serious issue in cases of acute proliferative (fast-progressing) diseases like acute leukemia.

Another problem is the fact autologous T cells may be compromised due to certain tumor-associated immunosuppression activities in some patients that render T cells dysfunctional. Other factors, such as previous lines of treatments, can also have a significant impact on T cells.

As a clever step to address the aforementioned drawbacks, "off-the-shelf" allogeneic CAR T cells are being developed and tested. Allogeneic CAR T cells are derived from healthy donors. According to the current phase of development so far, allogeneic CAR T cells have demonstrated multiple potential benefits including reduced manufacturing cost, and immediate availability.

# data[].attributes.attachment_link.description
An accomplished entrepreneur-advisor and innovative tactician who has worked extensively in Florida, New York, California, and Boston in Massachusetts, Richard DiVenuto serves as an advisor to two Biotechnology companies. In this role, Richard DiVenuto implements and monitors corporate stock options for the board of directors and employees.

# data[].attributes.headline
Project Edge- ULT X Speeds up Remote Computing of Large Data

# data[].attributes.subject
Project Edge- ULT X Speeds up Remote Computing of Large Data

# data[].attributes.body
An experienced consultant and advisor, Richard DiVenuto works with biotech and technology companies. Residing in Balmville, New York, with his wife and three children, Richard DiVenuto provides advice to investors who seek to invest in promising technology companies in California, Florida, and Boston, Massachusetts. One of the companies he has promoted is Vcinity Inc.

# data[].attributes.attachment_link.readable_text
An experienced consultant and advisor, Richard DiVenuto works with biotech and technology companies. Residing in Balmville, New York, with his wife and three children, Richard DiVenuto provides advice to investors who seek to invest in promising technology companies in California, Florida, and Boston, Massachusetts. One of the companies he has promoted is Vcinity Inc.

Project Edge (a tech company) ULT X is a product of combined hardware and software components or entirely software solutions specially designed to suit remote, public, Edge, private, and hybrid cloud applications. The product is built with features that significantly diminish operational latency in both premises and cloud data centers. Such undesired latency occurs when there is a need to remotely upload to or access large quantities of data in the cloud (which may be located thousands of miles away) while restricted to the wireless area network (WAN). While WAN works well over vast geographical distances, transferring huge amounts of data tends to push its performance to its limits.

With Project Edge's ULT X, Project Edge incorporates local area network speed into wireless area network delivery and allows remote users to have this advantage at their disposal. The remote user gains unparalleled access to large datasets anywhere. Project Edge's ULT X allows in-place data computing, which means the editing of data can be done without prior caching, staging, copying, or downloading from the database.

Categories Tags Posted on Technology Project Edge- ULT X

# data[].attributes.attachment_link.title
Project Edge- ULT X Speeds up Remote Computing of Large Data

# data[].attributes.attachment_link.description
An experienced consultant and advisor, Richard DiVenuto works with biotech and technology companies. Residing in Balmville, New York, with his wife and three children, Richard DiVenuto provides advice to investors who seek to invest in promising technology companies in California, Florida, and Boston, Massachusetts. One of the companies he has promoted is Vcinity Inc.